(NASDAQ: RVMD) Revolution Medicines's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Revolution Medicines's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast RVMD's revenue for 2025 to be $3,346,439,868, with the lowest RVMD revenue forecast at $3,346,439,868, and the highest RVMD revenue forecast at $3,346,439,868. On average, 1 Wall Street analysts forecast RVMD's revenue for 2026 to be $7,713,543,896, with the lowest RVMD revenue forecast at $7,713,543,896, and the highest RVMD revenue forecast at $7,713,543,896.
In 2027, RVMD is forecast to generate $31,236,227,468 in revenue, with the lowest revenue forecast at $6,267,138,219 and the highest revenue forecast at $101,043,892,681.